Similar articles for PMID: 25261780

Year	Number of Results
2006	2
2007	1
2008	4
2009	11
2010	4
2011	9
2012	22
2013	20
2014	23
2015	13
2016	7
2017	2
2018	2
2019	3
2020	1
2023	1
2024	0

1

Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.

Potard V, Rey D, Poizot-Martin I, Mokhtari S, Pradier C, Rozenbaum W, Brun-Vezinet F, Costagliola D; FHDH ANRS CO4 (French Hospital Database on HIV, Agence Nationale de Recherches sur le Sida, cohort 4). Potard V, et al. J Int AIDS Soc. 2014 Sep 25;17(1):19070. doi: 10.7448/IAS.17.1.19070. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25261780 Free PMC article.

2

Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.

Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, Tian M, Fredrick LM, Podsadecki TJ, Nilius AM. Reynes J, et al. HIV Clin Trials. 2011 Sep-Oct;12(5):255-67. doi: 10.1310/hct1205-255. HIV Clin Trials. 2011. PMID: 22180523 Clinical Trial.

3

Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.

Tan DH, Chan K, Raboud J, Cooper C, Montaner JS, Walmsley S, Hogg RS, Klein MB, Machouf N, Rourke SB, Tsoukas C, Loutfy MR; CANOC Collaboration. Tan DH, et al. J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):38-46. doi: 10.1097/QAI.0b013e3182282cfc. J Acquir Immune Defic Syndr. 2011. PMID: 21709570

4

Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).

Shaffer D, Hughes MD, Sawe F, Bao Y, Moses A, Hogg E, Lockman S, Currier J. Shaffer D, et al. J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):155-63. doi: 10.1097/QAI.0000000000000131. J Acquir Immune Defic Syndr. 2014. PMID: 24562349 Free PMC article. Clinical Trial.

5

A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz.

Domingo P, Gutierrez Mdel M, Gallego-Escuredo JM, Torres F, Mateo MG, Villarroya J, Lamarca K, Domingo JC, Vidal F, Villarroya F, Giralt M. Domingo P, et al. J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):457-65. doi: 10.1097/QAI.0000000000000205. J Acquir Immune Defic Syndr. 2014. PMID: 24820106 Clinical Trial.

6

Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.

Nishijima T, Gatanaga H, Shimbo T, Komatsu H, Endo T, Horiba M, Koga M, Naito T, Itoda I, Tei M, Fujii T, Takada K, Yamamoto M, Miyakawa T, Tanabe Y, Mitsuya H, Oka S; SPARE study team. Nishijima T, et al. PLoS One. 2013 Aug 8;8(8):e73639. doi: 10.1371/journal.pone.0073639. eCollection 2013. PLoS One. 2013. PMID: 23951362 Free PMC article. Clinical Trial.

7

Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.

Blanco JR, Caro-Murillo AM, Castaño MA, Olalla J, Domingo P, Arazo P, Gómez-Sirvent JL, Riera M, Pulido F, Vera F, Romero-Palacios A, Aguirrebengoa K, Portilla J, Ferrer P, Pedrol E. Blanco JR, et al. HIV Clin Trials. 2013 Sep-Oct;14(5):204-15. doi: 10.1310/hct1403-204. HIV Clin Trials. 2013. PMID: 24144897

8

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.

Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, Kumar PN, Sutherland-Phillips DH, Vavro C, Yau L, Wannamaker P, Shaefer MS; HEAT Study Team. Smith KY, et al. AIDS. 2009 Jul 31;23(12):1547-56. doi: 10.1097/QAD.0b013e32832cbcc2. AIDS. 2009. PMID: 19542866 Clinical Trial.

9

48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.

Patel DA, Snedecor SJ, Tang WY, Sudharshan L, Lim JW, Cuffe R, Pulgar S, Gilchrist KA, Camejo RR, Stephens J, Nichols G. Patel DA, et al. PLoS One. 2014 Sep 4;9(9):e105653. doi: 10.1371/journal.pone.0105653. eCollection 2014. PLoS One. 2014. PMID: 25188312 Free PMC article. Review.

10

Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.

Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E. Penazzato M, et al. Cochrane Database Syst Rev. 2014 May 22;2014(5):CD004772. doi: 10.1002/14651858.CD004772.pub4. Cochrane Database Syst Rev. 2014. PMID: 24852077 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

110 results

Results by year